These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 111274)

  • 1. Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation.
    Lipper S; Murphy DL; Slater S; Buchsbaum MS
    Psychopharmacology (Berl); 1979 Apr; 62(2):123-8. PubMed ID: 111274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients.
    Pickar D; Murphy DL; Cohen RM; Campbell IC; Lipper S
    Arch Gen Psychiatry; 1982 May; 39(5):535-40. PubMed ID: 7092487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man.
    Murphy DL; Lipper S; Slater S; Shiling D
    Psychopharmacology (Berl); 1979 Apr; 62(2):129-32. PubMed ID: 111275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline.
    Insel TR; Murphy DL; Cohen RM; Alterman I; Kilts C; Linnoila M
    Arch Gen Psychiatry; 1983 Jun; 40(6):605-12. PubMed ID: 6342562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline).
    Murphy DL; Karoum F; Pickar D; Cohen RM; Lipper S; Mellow AM; Tariot PN; Sunderland T
    J Neural Transm Suppl; 1998; 52():39-48. PubMed ID: 9564606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevation of plasma-prolactin by monoamine-oxidase inhibitors.
    Slater SL; Lipper S; Shiling DJ; Murphy DL
    Lancet; 1977 Aug; 2(8032):275-6. PubMed ID: 69882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks.
    Barbelivien A; Nyman L; Haapalinna A; Sirviö J
    Pharmacol Toxicol; 2001 Jun; 88(6):304-12. PubMed ID: 11453370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with clorgyline and pargyline differentially decreases clonidine-induced hypotension and bradycardia.
    Gutkind JS; Enero MA
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Sep; 327(3):189-92. PubMed ID: 6493360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of clorgyline and pargyline on deaminated metabolites of norepinephrine, dopamine and serotonin in human cerebrospinal fluid.
    Major LJ; Murphy DL; Lipper S; Gordon E
    J Neurochem; 1979 Jan; 32(1):229-31. PubMed ID: 759576
    [No Abstract]   [Full Text] [Related]  

  • 10. Clorgyline. A new treatment for patients with refractory rapid-cycling disorder.
    Potter WZ; Murphy DL; Wehr TA; Linnoila M; Goodwin FK
    Arch Gen Psychiatry; 1982 May; 39(5):505-10. PubMed ID: 6807254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Problems with the measurement of monoamine oxidase A protein concentration in mitochondrial preparations. Revised molecular activities and implications for estimating ratios of MAO A:MAO B molecules from radiochemical assay data.
    Riley LA; Denney RM
    Biochem Pharmacol; 1991 Oct; 42(10):1953-9. PubMed ID: 1741773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain.
    Olmos G; Gabilondo AM; Miralles A; Escriba PV; García-Sevilla JA
    Br J Pharmacol; 1993 Mar; 108(3):597-603. PubMed ID: 8385528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the monoamine oxidase inhibitors clorgyline and pargyline on the hyperphagia of obese mice.
    Feldman JM
    Behav Brain Res; 1988 Jul; 29(1-2):147-58. PubMed ID: 2840925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. REM sleep suppression induced by selective monoamine oxidase inhibitors.
    Cohen RM; Pickar D; Garnett D; Lipper S; Gillin JC; Murphy DL
    Psychopharmacology (Berl); 1982; 78(2):137-40. PubMed ID: 6817370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible subsensitization of alpha 2-adrenergic receptors by chronic monoamine oxidase inhibitor treatment in psychiatric patients.
    Siever LJ; Uhde TW; Murphy DL
    Psychiatry Res; 1982 Jun; 6(3):293-302. PubMed ID: 6287513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced changes in motor activity after selective MAO inhibition.
    Gianutsos G; Carlson GM; Godfrey JG
    Pharmacol Biochem Behav; 1983 Aug; 19(2):263-8. PubMed ID: 6634874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline.
    Fowler CJ; Mantle TJ; Tipton KF
    Biochem Pharmacol; 1982 Nov; 31(22):3555-61. PubMed ID: 6817759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between cytosolic monoamine oxidase and spin-labeled amphetamine and its modification by clorgyline and pargyline.
    Copeland ES; Campbell IC; Murphy DL
    Biochim Biophys Acta; 1983 Feb; 743(1):186-94. PubMed ID: 6824699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoamine oxidase in pancreatic islets, exocrine pancreas, and liver from rats. Characterization with clorgyline, deprenyl, pargyline, tranylcypromine, and amezinium.
    Lenzen S; Nahrstedt H; Panten U
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Nov; 324(3):190-5. PubMed ID: 6419132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain.
    Tadano T; Satoh S; Satoh N; Kisara K; Arai Y; Kim SK; Kinemuchi H
    J Pharmacol Exp Ther; 1989 Jul; 250(1):254-60. PubMed ID: 2501477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.